Quality is our promise.

Call us today! 1-888-502-2050

9

June
2015

category:

503b Compounding

Ophthalmologists and Patients Demand Quality Compounded Drugs at Affordable Prices

Access to compounding medications critical for ophthalmologists, patients http://www.healio.com/ophthalmology/practice-management/news/print/ocular-surgery-news/%7Bebef4371-1c0c-460d-b3cb-6e8d524915e2%7D/access-to-compounded-medications-critical-for-ophthalmologists-patients?page=1 Ocular Surgery News U.S. Edition, May 25, 2015 Richard L. Lindstrom, MD The decisions the FDA makes are critical to ophthalmologists and patients, especially in the anti-VEGF category. As I mentioned above, no generic anti-VEGF injectables are available. Lucentis (ranibizumab, Genentech) and Eylea, branded and patent-protected […]

read more

18

May
2015

category:

503b Compounding

New Poll Finds Strong Support For Effective FDA Regulation of Compounding Pharmacies

WASHINGTON, SEPT. 18, 2013 — Voters Expect to Be Informed If They Are Prescribed A Drug Not Approved By the FDA As Congress considers legislation to address the oversight of compounding pharmacies, a new, independent survey released today highlights the large gap between voters’ expectations that the medications they receive are FDA-approved and loopholes in […]

read more

29

September
2014

category:

503b Compounding

Clinigen Group plc Receives FDA’s First Ever Drug Shortage Assistance Award

URTON-ON-TRENT, England, Sep 29, 2014 (BUSINESS WIRE) — Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM:CLIN) the global specialty pharmaceutical company, today announces that it has received the first Drug Shortage Assistance Award from the US Food and Drug Administration (FDA)in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection. […]

read more